HCW Biologics Inc. (HCWB)
NASDAQ: HCWB · Real-Time Price · USD
4.500
+0.280 (6.64%)
At close: Oct 14, 2025, 4:00 PM EDT
4.460
-0.040 (-0.89%)
After-hours: Oct 14, 2025, 7:40 PM EDT
HCW Biologics Revenue
HCW Biologics had revenue of $6.55K in the quarter ending June 30, 2025, a decrease of -98.94%. This brings the company's revenue in the last twelve months to $832.84K, down -78.77% year-over-year. In the year 2024, HCW Biologics had annual revenue of $2.57M, down -9.68%.
Revenue (ttm)
$832.84K
Revenue Growth
-78.77%
P/S Ratio
6.21
Revenue / Employee
$23,134
Employees
36
Market Cap
9.71M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.57M | -275.00K | -9.68% |
| Dec 31, 2023 | 2.84M | -3.88M | -57.72% |
| Dec 31, 2022 | 6.72M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 4.10M | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
HCWB News
- 14 days ago - HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program - GlobeNewsWire
- 26 days ago - HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing - GlobeNewsWire
- 4 weeks ago - HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development - GlobeNewsWire
- 7 weeks ago - HCW Biologics' Shares Surge After Unveiling Next-Gen Cancer Immunotherapy Platform - Benzinga
- 7 weeks ago - HCW Biologics to Showcase its Novel Second-Generation Immune Checkpoint Inhibitor Identified as a Potential Gateway to a Multi-Billion Dollar Market - GlobeNewsWire
- 2 months ago - HCW Biologics Reports Second Quarter 2025 Business Highlights and Financial Results - GlobeNewsWire
- 3 months ago - HCW Biologics to Showcase Important Updates on IND-Enabling Studies and Preclinical Success of Its Novel Multi-Specific T-Cell Engagers Against Solid Tumors - GlobeNewsWire
- 3 months ago - HCW Biologics Regains Compliance with Nasdaq Capital Market Requirements - GlobeNewsWire